Dong-A ST said Thursday that Jublia, a toenail fungal treatment, has surpassed annual sales of 10 billion won ($89.3 million).
The drug, developed by Japan’s Kaken Pharmaceutical in 2014, is the only paste-form nail fungal infection treatment, also known as athlete’s foot, approved in Korea as an ETC (Ethical the Counter) drug. It has also received approval from the U.S. Food and Drug Administration.
Based on the company's shipment records, Jublia posted sales of about 10.1 billion won from the start of this year to Nov. 1.
In particular, after surpassing 4r billion won in just six months after its launch in June last year, the treatment has become a blockbuster product in its second year and has become a new treatment option for athlete's foot. The company expects to reach 12 billion won in sales by the end of this year.
The drug's benefits include few side effects, which are advantages of topical applications, as well as similarly high therapeutic effect to that of oral medications. Also, the drug does not require the patient to grate their toenail.
“Jublia has achieved yearly sales of more than 10 billion won in the second year of its launch with a high therapeutic effect on patients, who are hesitant to receive treatment due to limited effects of conventional nail athlete's foot treatment and side effects such as hepatotoxicity,” a company official said.
As 25 to 40 percent of patients experience a treatment failure for athlete's foot, Dong-A ST will continue to make Jublia the best treatment option for medical staff and patients, he added.
To this end, the company is conducting phase 4 clinical trials at nine medical institutions in Korea.
<© Korea Biomedical Review, All rights reserved.>